Sugi Predict

Sugi Predict / Targets / HPSE

HPSE

Heparanase · Q9Y251 · HPSE on Sugi Atlas →

34,257 patent compounds predicted against HPSE, 17,769 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Methane Methane (SCHEMBL506232) 0.70 16/20
Potassium Ion Potassium Ion (SCHEMBL380009) 0.32 14/20
SCHEMBL507169 SCHEMBL507169 0.73 13/20
Sucrosofate Sucrosofate (SCHEMBL145069) 0.36 13/20
Sucrosofate Sucrosofate (SCHEMBL145070) 0.36 13/20
Sucrosofate Sucrosofate (SCHEMBL921799) 0.35 13/20
Fondaparinux Fondaparinux (SCHEMBL4937) 0.73 12/20
Methane Methane (SCHEMBL505763) 0.70 11/20
SCHEMBL728827 SCHEMBL728827 0.61 10/20
Water Water (SCHEMBL41379) 0.34 10/20
SCHEMBL875405 SCHEMBL875405 0.54 9/20
SCHEMBL943034 SCHEMBL943034 1.00 8/20
SCHEMBL980732 SCHEMBL980732 0.59 8/20
SCHEMBL883756 SCHEMBL883756 0.51 8/20
SCHEMBL416518 SCHEMBL416518 0.53 7/20
SCHEMBL883351 SCHEMBL883351 0.51 7/20
SCHEMBL439112 SCHEMBL439112 0.51 7/20
SCHEMBL182360 SCHEMBL182360 0.55 6/20
Suramin Suramin (SCHEMBL3161) 1.00 5/20
SCHEMBL375471 SCHEMBL375471 0.80 5/20

Clinical trials — most relevant to HPSE by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Cannabidiol in Sanfilippo Syndrome PHASE2/PHASE3RECRUITING
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment PHASE2/PHASE3COMPLETED
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) PHASE3ACTIVE_NOT_RECRUITING
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients PHASE3COMPLETED
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients PHASE1/PHASE2COMPLETED
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease PHASE2UNKNOWN
Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease PHASE2COMPLETED
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI PHASE2UNKNOWN
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) PHASE1/PHASE2COMPLETED
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB PHASE2COMPLETED
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers PHASE1COMPLETED
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients nanCOMPLETED
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome nanRECRUITING
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome nanCOMPLETED
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) nanCOMPLETED
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome) nanCOMPLETED
Biomarker for Hurler Disease (BioHurler) nanWITHDRAWN
Chest Wall Deformities in Children - Epidemiological Data nanCOMPLETED
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1 nanUNKNOWN
Urine Biomarker for Stone Recurrence nanCOMPLETED
Perioperative Plasma Levels of Glycocalyx Markers in Colon Surgery. nanUNKNOWN
Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH) nanUNKNOWN
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC nanRECRUITING
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital nanNOT_YET_RECRUITING
A Natural History Study of Sanfilippo Syndrome Type D nanCOMPLETED
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HPSE binder may also engage these)

ProteinNameSimilarity
Q71RP1 — 1.000 Q71RP1 →
Q6YGZ1 — 0.996 Q6YGZ1 →
Q9MYY0 — 0.993 Q9MYY0 →
Q90YK5 — 0.972 Q90YK5 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.970 landscape →
Q5NDF0 — 0.967 Q5NDF0 →
Q8R4K8 — 0.967 Q8R4K8 →
Q5NDE9 — 0.967 Q5NDE9 →
Q5NDE3 — 0.966 Q5NDE3 →
Q7TN16 — 0.965 Q7TN16 →
Q794F9 — 0.965 Q794F9 →
Q8WP17 — 0.964 Q8WP17 →
Q6NRQ1 — 0.964 Q6NRQ1 →
Q9Z2Y9 — 0.964 Q9Z2Y9 →
Q5NDE7 — 0.963 Q5NDE7 →
Q9UEF7 — 0.963 Q9UEF7 →
Q5M900 — 0.962 Q5M900 →
STS Steryl-sulfatase 0.962 landscape →
Q5RFU0 — 0.962 Q5RFU0 →
Q5NDF1 — 0.961 Q5NDF1 →
Q8NAT1 — 0.961 Q8NAT1 →
Q64610 — 0.961 Q64610 →
Q6DYE8 — 0.961 Q6DYE8 →
Q8BW41 — 0.961 Q8BW41 →
Q5NDE8 — 0.961 Q5NDE8 →
Q13219 — 0.961 Q13219 →
Q9R1E6 — 0.961 Q9R1E6 →
Q9BRR6 — 0.961 Q9BRR6 →
F1QR43 — 0.960 F1QR43 →
Q6A198 — 0.960 Q6A198 →